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 Osteogenesis imperfecta (OI) is an autosomal-dominant
connective tissue disorder characterized by brittle bones to-
gether with associated features such as short stature, dentino-
genesis imperfecta, hyperlaxity of ligaments and skin, blue
sclera, and hearing loss [1]. The ocular manifestations of OI
are not usually sight threatening and typically consist of blue
sclerae. Other ocular manifestations that may occur include
perinuclear or cortical cataract, megalocornea, microcornea,
keratoconus, nystagmus, glaucoma, ptosis, etc. The minimum
prevalence of OI is estimated to be 1/10,000-1/30,000 [1,2].
Traditionally, it is usually classified into four types depending
on phenotype and severity [3,4]. Type I is the most common
and mildest deforming. Type II is the most severe and is lethal
in the perinatal period. Type III is severely deforming, and
fractures are often present at birth. Type IV is moderately de-
forming; its severity is between Type I and Type III.
More than 250 mutations in one of the two genes, COL1A1
and COL1A2, which encode the proα1 and proα2 chains of
collagen I, respectively, have been found in unrelated probands
with the disease. Most of these mutations are single nucle-
otide changes, mostly resulting in a substitution for a glycine
residue and disrupting the continuous Gly-X-Y sequence of
the collagen triple helix. Others are in-frame, single exon splic-
ing defects, and a few are deletions, duplications, or inser-
tions [1].
To identify the genetic defect of OI type I in a large Chi-
nese family of five generations, we carried out linkage analy-
sis and identified a COL1A1 nonsense mutation in a Chinese
OI type I family. In exon 36 of COL1A1 gene, a C to T transi-
tion at position 2,464 resulted in a glutamine (Gln) to stop
codon substitution at codon 644 (Q644X). This mutation
(Q644X) appeared to be novel, which is neither reported in
the literature nor registered in the database of human type I
and type III collagen mutations. We also found that the central
corneal thickness (CCT) of the OI patients were much lower
than normal.
METHODS
DNA specimens:  The protocol for the study was approved by
the Ethics Committee of our institute. Informed consent was
obtained from all family members participating in this study.
The family comprised 22 affected individuals from a five gen-
eration pedigree, originating from the Hebei province, China.
The study consisted of 17 members, including 8 affected indi-
viduals, 6 unaffected individuals, and 3 normal controls (Fig-
ure 1).
Clinical evaluations:  The past history was investigated
and the systems review was performed. The detailed ocular
examinations of the proband were performed and some pa-
rameters were measured including vision, IOP, CCT, ocular
axis length, and corneal curvature.
Genotyping:  Exclusion analysis was performed by allele
sharing of the microsatellite markers, which were linked with
the known OI loci. Genotyping was performed using
microsatellite markers D17S1293, D17S1180, D17S1319, and
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360D17S788 at 17q 11.2-22. The oligonucleotide primer se-
quences were taken from NCBI and GDB.
Linkage analysis:  A two-point LOD score (Z) was calcu-
lated using the MLINK subprogram of the Linkage package
(version 5.1). The mode of inheritance was considered to be
autosomal dominant with 95% penetrance. The gene frequency
was set at 1/15,000. As the allelic frequencies of the polymor-
phic markers are unknown in the Chinese population, they
were considered to be equally distributed.
DNA sequencing:  COL1A1 (NM_000088) was screened
for mutations by direct sequencing. PCR products of the 51
exons and flanking intron sequences of COL1A1 were se-
quenced on an ABI-3730 DNA Analyzer (Applied Biosystems,
Foster City, CA). Oligonucleotide primers and conditions for
amplification are available upon request.
Denaturing HPLC:  To screen for the mutation identified
in the patients, on remaining patients, family members, and
100 normal control subjects in exon 36 of the COL1A1 gene,
Denaturing (D)HPLC was involved by using a commercial
system (Wave DHPLC; Transgenomic, San Jose, CA). The
sequence for DHPLC was: 5'-CCT CCA TTA CTG CTC CTC
CCC-3' for the forward primer, and 5'-GAG GGC CAA GCC
ACT CAC AA-3' for the reverse primer. The touchdown PCR
profile was used, 95 °C during 5 min, then 10 cycles of dena-
turation at 95 °C (30 s), primer annealing at 63 °C (30 s) with
the temperature decreasing 0.8 °C at each cycle, polymeriza-
tion for 30 s at 72 °C; followed by 35 cycles with the same
profile for denaturation and polymerization but with a con-
stant annealing temperature of 55 °C. Polymerization was
completed by an incubation of 10 min at 72 °C. DHPLC was
performed as follows: initial concentration at 51% of buffer A
(0.1 M triethylammonium acetate-TEAA; Transgenomic), and
49% of buffer B (0.1 M TEAA containing 25% acetonitrile;
Transgenomic) at 64.7 °C.
RESULTS
Clinical data:  All affected individuals in the family had frac-
tured their long bones several times from minor trauma and
their sclerae have been blue since birth. The proband (V:3)
was a 14-year-old boy with blue sclerae (Figure 2). His uncor-
rected visual acuity was OD, 20/10; OS, 20/10. His intraocu-
lar pressures (Goldmann tonometry) were OD, 14.7 mmHg;
OS, 18.3 mmHg. His corneal curvature measurements were
OD, K1 43.3, K2 43.6; OS, K1 43.0, K2 44.0. The ocular axis
©2007 Molecular Vision Molecular Vision 2007; 13:360-65 <http://www.molvis.org/molvis/v13/a39/>
Figure 1. The osteogenesis imperfecta pedigree and haplotype analysis.  Pedigree and haplotype analysis of the OI family showing segregation
of four microsatellite markers on chromosome 17. Squares symbolize males, and circles represent females. Black and white lines denote
affected and unaffected status, respectively.
361lengths were normal: OD, 24.03 mm; OS, 24.23 mm. His CCT
were low: OD, 434 mm; OS, 441 mm. No systemic or other
ocular anomalies were observed in the patients.
Linkage and haplotype analysis:  Allele-sharing analysis
confirmed the linkage of the disease in the family with COL1A1
and no linkage with COL1A2 (data not shown). Haplotype
analysis showed that all the affected individuals shared a com-
mon haplotype with markers D17S1293, D17S1180,
D17S1319, and D17S788 at 17q11.2-22 (Figure 1). Signifi-
cant evidence of linkage was observed with microsatellite
markers D17S1180 (LOD score [Z]=2.91, at recombination
fraction [θ]=0.0) and D17S1319 (Z=2.20, at θ=0.0), respec-
tively (Table 1).
Mutation detection of COL1A1: Direct cycle sequencing
of the amplified fragments of COL1A1 in two affected indi-
viduals identified a single base alteration of C2464T (Figure
3) in exon 36 of COL1A1, which resulted in a substitution of
Gln at codon 644 to a stop codon (Q644X). Denaturing HPLC
analysis confirmed this mutation, which cosegregated with all
affected individuals in the family, and was not observed in
any of the unaffected family members or 100 normal controls.
The remainder of the coding sequence did not show any
change.
DISCUSSION
 OI is an autosomal-dominant disorder of connective tissue
associated with defects in the structure or synthesis of type I
collagen [5,6]. OI is clinically characterized by increased bone
fragility with a propensity to fracture, often resulting in skel-
etal deformity. Typical manifestations also include hearing loss,
dental abnormalities, and blue sclerae.
Although the spectrum of clinical features is wide, and
an OI patient with Rieger’s anomaly has been reported [7],
the typical ocular finding is blue sclera. The sclerae of OI can
vary in color from normal to a slightly bluish or slate color to
a bright blue [8]. The blue sclerae may result from thinning of
the abnormal sclera [9], the uniformity of the scleral collagen
fibers, the reduced number of collagen bundles, and the in-
creased mucoid components within the sclera [10]. All of these
alterations in the ultrastructure of the sclera may, in essence,
allow it to behave more like corneal tissue, transmitting the
light reflected from the underlying uveal pigment and giving
it the bluish color observed clinically. Histopathologic and elec-
tron-microscopic examination of an eye from an OI patient
revealed that the sclera was moderately thinned especially at
the equator; the Bowman’s layer in the cornea was absent;
and the collagen fibers of the cornea and the sclera were nar-
rower than in the control [10].
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Figure 2. The blue sclera of affected individuals.  The proband (V:3)
was a 14-year-old boy, whose sclerae were blue. The thinning of the
sclera makes it possible to transmit the light reflected from the un-
derlying uveal pigment and gives it the bluish color observed clini-
cally. His uncorrected visual acuity was OD, 20/10; OS, 20/10. His
intraoclar pressures (Goldmann tonometry) were OD, 14.7 mmHg;
OS, 18.3 mmHg. His keratometry evaluation revealed the following:
OD, K1 43.3, K2 43.6; OS, K1 43.0, K2 44.0. The ocular axis lengths
were normal: OD, 24.03 mm; OS, 24.23 mm. His CCT were low:
OD, 434 mm; OS, 441 mm. The other ocular examinations including
the anterior chamber and the fundus had no positive findings.
Figure 3. DNA sequence chromatograms of the unaffected and af-
fected members in the family.  A single transition was observed at
position 2464 (C>T) of COL1A1, causing a substitution of Gln to a
stop codon at codon 644 (Q644X). This resulted in a truncated pro-
tein.
TABLE 1. TWO-POINT LOD SCORES FOR LINKAGE BETWEEN THE OI
LOCUS AND 17Q11.2-22 MARKERS
                 LOD scores at recombination
                       for values of θ
           ---------------------------------------
 Marker     0     0.1    0.2    0.3    0.4    Zmax
--------   ----   ----   ----   ----   ----   ----
D17S1293   2.04   1.76   1.32   0.78   0.26   2.04
D17S1180   2.91   2.23   1.52   0.80   0.20   2.91
D17S1319   2.20   1.62   1.06   0.57   0.20   2.20
D17S788    0.37   0.27   0.17   0.08   0.02   0.37
Two-point LOD scores of 2.91 at θ=0.0 with marker D17S1180, 2.20
at θ=0.0 with marker D17S1319, and 2.04 at θ=0.0 with marker
D17S1293 were obtained.
362As observed in our study, the CCT of OI patients is often
low while the vision is usually not affected. Moreover, both
CCT and ocular rigidity are negatively correlated with the pres-
ence of blue sclerae [11]. Therefore, for such patients, an oph-
thalmologist must be aware of an artificially low intraocular
pressure (IOP) measurement resulting from the low CCT and
the decreased ocular rigidity. Furthermore, when considering
a keratorefractive treatment, the clinician should evaluate care-
fully the CCT to avoid unexpected results or complications
[11]. In our study, the IOP of the left eye of the proband was
18.3 mmHg, and it may be harmful to such a low CCT. It was
suggested to the proband that he come back to the hospital for
eye examinations every six months.
The cornea and the sclerae are known to be thinner in OI
patients due to the defective collagen synthesis. The eyeball
may distend because of the IOP. We expected longer ocular
anteroposterior diameter in such patients, and we measured
this parameter. However, the ocular axis lengths of our 14-
year-old proband were within the normal range. We speculate
that the ocular axis length of OI patients may be in correlation
with their age. As the patient ages, the “cumulative effect” of
the persistent intraocular pressure on the relatively thin and
weak eyeball may lengthen the ocular axis.
Since 1980s, when the mutations in COL1A1/COL1A2
were first described, over 250 mutations in these two genes
have been found in OI patients with various phenotype from
diverse racial and ethnic groups (database of human type I
and type III collagen mutations and the Gene Mutation Data-
base). The vast majority are missense point mutations that
convert codons for the obligate glycines in the triple helix of
type I collagen to codons for amino acids with bulkier side
chains [12-14]. The helical domain of type I collagen is com-
posed of uninterrupted repeats of the sequence Gly-X-Y, in
which Gly is glycine, and X and Y could be any residue but
cysteine or tryptophan. The presence of glycine at every third
residue is crucial to helix formation because its small side chain
can be accommodated in the spatial constraints of the interior
of the helical trimer [15]. Therefore, the substitution of a gly-
cine residue by an amino acid with a bulky, polar, or charged
side chain will distort the conformation of the triple helix and
perturb normal collagen assembly in the cell, secretion from
the cell, or fibril assembly in the extracellular spaces, and fi-
nally, often lead to a severe OI phenotype (type II) [13,16].
Although several, apparently more common, mutations
have been reported in more than one unrelated individual or
family with a similar OI phenotype [12,14,15,17,18], the rela-
tionships between the phenotype and genotype are not clear
yet. In the vast majority of cases, the mutations are “private”
in that they have only been reported in one person or family
[19]. In spite of this, we can still obtain some rough correla-
tion between the phenotype and genotype, such as the more
NH2-terminal a serine substitution is located, the more severe
the phenotype tends to be [20]. Glycine substitutions at the
COOH-terminal half of the protein result in a more severe
phenotype, while mutations at the NH2-terminal half tend to
manifest in a less severe phenotype [21]. The missense point
mutation occurring at glycine codon tends to result in a lethal
phenotype, while the mutation creating a premature stop codon
often leads to a mild, type I phenotype [13] etc. In conclusion,
the severity of the phenotype is strongly associated with the
specific site of the mutation.
The mutation analysis of OI is a labor intensive, expen-
sive process due to the “private” nature of offending muta-
tions and their nonclustered distribution in considerably sized
genes [22]. Therefore, in our study, members of the family
were genotyped first with microsatellite markers at the two
known loci of OI. Haplotype analysis showed that the affected
individuals in this family shared a common haplotype with
four markers, within the region of 17q11.2-22, where the
COL1A1 gene is located. After screening COL1A1 for muta-
tions by direct sequencing, we identified a C>T transition in
exon 36 of the gene. The transition C2464T located in exon
36 was predicted to cause a substitution of Gln to a stop codon
at codon 644 (Q644X). DHPLC was used as a rapid, inexpen-
sive method to confirm the mutation. The results showed that
this mutation cosegregated with all affected individuals and
was not observed in unaffected family members or 100 nor-
mal unrelated individuals.
The nonsense mutation in our study, Q644X, could cause
one α1(I) allele to be functionally void. The transcription prod-
ucts of such a COL1A1 gene are usually unstable and sub-
jected to degradation via nonsense-mediated mRNA decay
pathways (NMD), ultimately producing a truncated protein.
The NMD is a universal phenomenon and describes the deg-
radation of mRNA transcripts that contain premature termi-
nation signals [23]. For the COL1A1 gene, NMD is a nuclear
phenomenon. It targets mRNA rather than hnRNA for degra-
dation [24]. The recognition and decay of nonsense contain-
ing COL1A1 mRNA occurs either during or after splicing but
prior to cytoplasmic translation [24]. Regardless of the posi-
tion of the mutation within the gene or its relative position
within an exon, the steady-state amounts of mRNA from the
mutant allele can be reduced markedly by NMD in both cellu-
lar and nuclear RNA extracts of cells from affected individu-
als [23]. Bioinformatic analyses also showed that Q644 is lo-
cated in a highly conserved region (data not shown). As a re-
sult, a reduced amount of structurally normal collagen type I
chains are expressed by fibroblasts of affected individuals, thus
leading to OI type I [13-15,19,25]. This study confirms that
the decreased expression of proα1(I) chains resulting from
premature-termination codons or RNA-splicing defects in the
COL1A1 gene often leads to the mildest OI.
To our knowledge, 13 nonsense mutations have been de-
scribed at the collagen domain of COL1A1: R42X [13], R75X
[22], R183X [13,14,22], R237X [18,22], R294X [26], R420X
[27], E500X [14], R519X [13], R704X [28], Q779X [22],
R848X [22,28], R963X [12,29], and Q644X (in our study).
Two have been found at the COOH-terminal domain: W1269X
[26], W1325X [28]. All of the aforenamed nonsense muta-
tions predictably led to OI type I except W1269X, which re-
sulted in OI type IV. The majority of these converted CGA,
which encodes arginine to TGA and creates a premature stop
codon. Our study is the second reported nonsense mutation
converting a glutamine codon to a premature stop codon. These
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363results suggest that close attention should be paid to arginine
codons when screening the COL1A1 for mutations.
Until our report, there were seven point mutations in exon
36 of COL1A1 that were registered in the Human Type I and
Type III Collagen Mutation Database. All of these mutations
were missense mutations that converted a glycine codon to a
serine, asparagine, or an arginine codon. Most of these muta-
tions resulted in the severe OI type II. The Q644X in our study
is the first nonsense mutation observed to occur in exon 36,
and it also indicates that the coding sequence in exon 36 is
essential for COL1A1’s function.
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